HER2-targeted therapies — a role beyond breast cancer

By D. Oh, Y. Bang. Nature Reviews Clinical Oncology, 2019

908 citations recorded by the source corpus.

Subfields: Oncology, Radiology, Nuclear Medicine and Imaging

View Paper: https://www.semanticscholar.org/paper/63ca08e74655f9b8c78f9ccd8cb297c245285da7

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

1. A. Oaknin
2. Funda Meric-Bernstam
3. Yajun Wang
4. T. Gong
5. K. Jung
6. Do-Youn Oh
7. Susana Banerjee
8. L. Manso

Citations in the corpus

• Nanomedicine in cancer therapy (2023, background): “173,174 A signi fi cant number of breast, gastric, and ovarian cancers exhibit an elevated expression of HER2.”
• Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial (2023, background): “5”